The DESolveTM Myolimus-Eluting Bioresorbable Coronary Scaffold (Elixir Medical Corporation, Sunnyvale, CA) is a novel bioresorbable vascular scaffold device that combines a PLLA-based scaffold coated with a potent antiproliferative sirolimus analog agent Myolimus (3 mcg per mm of scaffold length). Methods: A total of 15 patients with single de novo coronary artery lesions Յ14mm in vessels 2.5-3.75 mm in diameter were enrolled in this prospective, multi-center, single-arm, first-in-man study, and underwent serial angiographic studies at baseline/ index and 6 months follow-up. Primary endpoint was angiographic in-scaffold late lumen loss, as determined by quantitative coronary angiography (QCA) analysis performed by an independent angiographci core laboratory. Results: Overall, 14 patients/lesions were available for paired analysis. The Right coronary artery was the most prevalent lesion location (43%) and lesion class according to the ACC/AHA classification demonstrated type A in 36%, type B1 in 29% and type B2 in (36%). Baseline QCA showed mean lesion length, reference diameter (RD), minimum lumen diameter (MLD) and % diameter stenosis (DS) of 8.95Ϯ2.64mm, 2.65Ϯ0.32mm, 0.81Ϯ0.29mm and 70.0Ϯ10.5%, respectively. During procedure, predilatation was performed in 93%, postdilatation was performed in 29%, and final TIMI flow was achieved in 100%. Final and 6-month follow-up QCA analyses are shown in the Table. Overall, there was only 1 case of in-segment binary restenosis, which involved the proximal edge outside the scaffold.
Variable
In-Scaffold (N‫)41؍‬ Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands, 2 Cardialysis B.V., Rotterdam, Netherlands, 3 Abott Vascular International BVBA, Diegem, Belgium, 4 Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil Background: Side branch occlusion (SBO) contributes to the periprocedural myocardial infarction (MI), which has been associated with unfavorable late clinical outcomes. However, the incidence and acute clinical outcomes of SBO after bioresorbable vascular scaffold (BVS) implantation has been unexplored. Methods: Amongst consecutive 469 patients who were enrolled in the ABSORB-EXTEND single-arm trial from January 2010 to January 2012, a total of 1127 side branches in 435 patients were evaluated. Although major side branches Ն 2 mm in diameter was excluded per protocol, any visible side branches originating within to-be-scaffolded segment or its 5 mm-proximal and -distal margins were included in the angiographic assessment. SBO was defined as a reduction in thrombolysis in myocardial infarction (TIMI) flow to grade 0 or 1. Results: Pre-procedure reference vessel diameter (RVD) and percent diameter stenosis were 2.62 mm and 58.6 % in the main vessel, and 1.18 mm and 20.0 % in the side branch, respectively. Post-procedure SBO was observed in 67 out of 1127 side branches (5.9 %), while it was 9 out of 537 side branches with a RVD of Ͼ 1.0 mm (1.7 %). Amongst 67 occluded side branches, 60 (89.6 %) were originated within the obstruction segment in the main vessel, which was automatically delineated by quantitative coronary angiography. Periprocedural Non-Q-wave MI (NQMI) according to the protocol definition was adjudicated in 5 patients (mean ratio of peak CK and CKMB to upper limit of normal were 2.82 and 4.61, respectively) amongst 61 patients with the angiographic evidence of SBO post-procedure (8.2 %). 
Conclusions:
At 4 years, no difference in overall MACCE was found between treatment groups. There was an advantage of PCI in stroke and a reduced need for repeat revascularization with CABG. SYNTAX and other recent studies of LM disease suggest that in some patients (those with less complex lesions as defined by low or intermediate SYNTAX Scores), PCI using drug-eluting stents may be as effective but less invasive than CABG. CABG should be used for patients with more complex anatomical disease (high SYNTAX Scores). Five-year data will be available at the time of presentation.
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Final Thomas' Hospital, London, United Kingdom, 3 Guy's and St. Thomas' Hospital, London, United Kingdom, 4 EMO GVM Centro Cuore Columbus srl, Milan, Italy, 5 Baylor Healthcare System, Plano, USA, 6 Erasmus MC, Rotterdam, The Netherlands, 7 Institut Hospitalier Jacques Cartier, Massy, France, 8 Mayo Clinic College of Medicine, Rochester, USA, 9 Evanston Hospital, Evanston, USA, 10 University Hospital Uppsala, Uppsala, Sweden, Uppsala, Uppsala, 11 Boston Scientific Corporation, Marlborough, MA, Rotterdam, Netherlands Background: In patients with severe, multivessel coronary disease, coronary artery bypass grafting (CABG) has been considered the standard of care. We will present 5-year outcomes in the 3VD subgroup of patients in SYNTAX. Methods: SYNTAX is a randomized clinical trial with nested registries. A cardiac surgeon and interventional cardiologist screened consecutive patients with de novo 3VD and/or LM disease. After informed consent, the patient was randomized if suitable for equivalent revascularization with either treatment; otherwise, they were enrolled in a nested registry. Analysis of the 3VD patient cohort was prespecified. Results: In the 3VD subgroup at 4 years, MACCE was significantly higher in patients with percutaneous coronary revascularization (PCI) compared with CABG patients. The rates of composite death/stroke/MI, death, MI, and repeat revascularization were increased in PCI patients; however, stroke was similar between groups at 4 years (Table) . Conclusions: This will be the first presentation of the final 5-year outcomes in the 3VD patient population of SYNTAX. Four-year results suggest that CABG remains the standard of care for patients with complex lesions (intermediate or high SYNTAX Score). With less complex disease (low SYNTAX Scores), PCI is an acceptable revascularization alternative.
